Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) have been given an average recommendation of “Moderate Buy” by the seven analysts that are presently covering the company, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $12.17.

Several analysts recently commented on the stock. Leerink Partners began coverage on shares of Ironwood Pharmaceuticals in a report on Monday, September 9th. They set a “market perform” rating and a $5.00 price target for the company. StockNews.com upgraded shares of Ironwood Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, July 16th. Wells Fargo & Company cut their price objective on Ironwood Pharmaceuticals from $14.00 to $12.00 and set an “overweight” rating for the company in a report on Friday, August 9th. Capital One Financial downgraded Ironwood Pharmaceuticals from an “overweight” rating to an “equal weight” rating and lowered their target price for the company from $12.00 to $4.00 in a research note on Thursday, August 8th. Finally, Leerink Partnrs raised Ironwood Pharmaceuticals to a “hold” rating in a research note on Monday, September 9th.

Ironwood Pharmaceuticals Trading Down 1.3 %

Shares of NASDAQ IRWD opened at $4.44 on Friday. Ironwood Pharmaceuticals has a one year low of $3.79 and a one year high of $15.70. The business has a 50-day moving average price of $4.45 and a two-hundred day moving average price of $6.03. The firm has a market capitalization of $694.99 million, a PE ratio of -0.65 and a beta of 0.48.

Insiders Place Their Bets

In other news, insider Minardo John sold 9,910 shares of the stock in a transaction dated Monday, August 12th. The stock was sold at an average price of $4.27, for a total transaction of $42,315.70. Following the transaction, the insider now owns 284,661 shares of the company’s stock, valued at approximately $1,215,502.47. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 12.90% of the company’s stock.

Institutional Trading of Ironwood Pharmaceuticals

Several large investors have recently modified their holdings of the company. Vanguard Group Inc. raised its holdings in Ironwood Pharmaceuticals by 21.8% in the 1st quarter. Vanguard Group Inc. now owns 19,521,366 shares of the biotechnology company’s stock worth $170,031,000 after acquiring an additional 3,487,821 shares during the period. Pacer Advisors Inc. increased its stake in shares of Ironwood Pharmaceuticals by 23.6% in the second quarter. Pacer Advisors Inc. now owns 8,907,639 shares of the biotechnology company’s stock worth $58,078,000 after purchasing an additional 1,701,452 shares during the period. Renaissance Technologies LLC lifted its position in shares of Ironwood Pharmaceuticals by 20.7% during the 2nd quarter. Renaissance Technologies LLC now owns 8,571,898 shares of the biotechnology company’s stock worth $55,889,000 after purchasing an additional 1,472,097 shares during the last quarter. Armistice Capital LLC boosted its stake in Ironwood Pharmaceuticals by 44.4% during the 2nd quarter. Armistice Capital LLC now owns 7,800,000 shares of the biotechnology company’s stock valued at $50,856,000 after purchasing an additional 2,400,000 shares during the period. Finally, Jacobs Levy Equity Management Inc. grew its holdings in Ironwood Pharmaceuticals by 40.8% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 4,235,580 shares of the biotechnology company’s stock valued at $36,892,000 after buying an additional 1,226,377 shares during the last quarter.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.